journal article·2024-08-21Open access

Acidity-Responsive Fe-PDA@CaCO3 Nanoparticles for Photothermal-Enhanced Calcium-Overload- and Reactive-Oxygen-Species-Mediated Tumor Therapy

Fan Zhao, Chen Wang, Heng Wang, Yao Ying, Wangchang Li, Juan Li, Jingwu Zheng, Liang Qiao, Shenglei Che, Jing Yu

ACS Applied Materials & Interfaces· Volume 16· Issue 33

Abstract

Calcium-overload-mediated tumor therapy has received considerable interest in oncology. However, its efficacy has been proven to be inadequate due to insufficient calcium ion concentration at the tumor site coupled with challenges in facilitating efficient calcium uptake by tumors, leading to unsatisfactory therapeutic outcomes. In the present study, calcium carbonate nanoshell mineralized ferric polydopamine nanoparticles (Fe-PDA@CaCO 3 NPs) were prepared for achieving Ca 2+ -overload-mediated tumor therapy. Upon entering the tumor site, the pH-responsive CaCO 3 layer, acting as a “Ca 2+ storage pool”, rapidly degraded and released high quantities of free Ca 2+ within the weakly acidic environment. The Fe-PDA core, with its excellent photothermal conversion properties, could significantly increase the temperature upon exposure to near-infrared (NIR) light irradiation, thereby activating the TRPV1 channel and leading to a large influx of released Ca 2+ into the cytoplasm. Furthermore, the exposed Fe-PDA core could react with the tumor-overexpressed hydrogen peroxide (H 2 O 2 ) to efficiently produce hydroxyl radicals (•OH), significantly increasing intracellular reactive oxygen species (ROS) levels and thus inhibiting the activity of the Ca 2+ efflux pump, resulting in a high intracellular Ca 2+ concentration. Ultimately, the increase in calcium/ROS levels could disrupt mitochondrial homeostasis and activate the apoptosis pathway. The current work presents a promising approach for tumor therapy using photothermal-enhanced calcium-overload-mediated ion interference therapy and chemodynamic therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Genetics and Neurodevelopmental Disorders · Hormonal Regulation and Hypertension

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Materials Science and Engineering, Zhejiang University of Technology, Hangzhou 310014, China

Research Center of Magnetic and Electronic Materials, Zhejiang University of Technology, Hangzhou 310014, China

Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou 310014, China

Funding

Fundamental Research Funds for the Provincial Universities of Zhejiang · National Natural Science Foundation of China · Zhejiang University of Technology · Natural Science Foundation of Zhejiang Province

References (39)

Show source-provided references
1. 10.1002/viw2.1810.1002/viw2.18 ↗
2. 10.1021/acsnano.2c0553210.1021/acsnano.2c05532 ↗
3. 10.1002/smll.20230037010.1002/smll.202300370 ↗
4. 10.1002/anie.20231757810.1002/anie.202317578 ↗
5. 10.1016/j.chempr.2021.11.02010.1016/j.chempr.2021.11.020 ↗
6. 10.1021/acsami.4c0010910.1021/acsami.4c00109 ↗
7. 10.1016/j.chempr.2019.06.00310.1016/j.chempr.2019.06.003 ↗
8. 10.1016/j.cej.2023.14627710.1016/j.cej.2023.146277 ↗
9. 10.1016/j.jcis.2022.03.08410.1016/j.jcis.2022.03.084 ↗
10. 10.1186/s12951-023-02090-z10.1186/s12951-023-02090-z ↗
11. 10.1038/s41467-021-26655-410.1038/s41467-021-26655-4 ↗
12. 10.1016/j.nantod.2023.10197410.1016/j.nantod.2023.101974 ↗
13. 10.1021/acsami.2c0255210.1021/acsami.2c02552 ↗
14. 10.1016/j.cej.2023.14247810.1016/j.cej.2023.142478 ↗
15. 10.1039/D3BM01430D10.1039/D3BM01430D ↗
16. 10.1002/adhm.20217008810.1002/adhm.202170088 ↗
17. 10.1038/s41467-017-02657-z10.1038/s41467-017-02657-z ↗
18. 10.1002/adfm.20231185310.1002/adfm.202311853 ↗
19. 10.1002/smll.20210336410.1002/smll.202103364 ↗
20. 10.1021/acs.nanolett.3c0370110.1021/acs.nanolett.3c03701 ↗
21. 10.1002/adma.20210843510.1002/adma.202108435 ↗
22. 10.1039/D1TB02351A10.1039/D1TB02351A ↗
23. 10.1038/s41467-023-38128-x10.1038/s41467-023-38128-x ↗
24. 10.1002/advs.20210024110.1002/advs.202100241 ↗
25. 10.1186/s12951-021-01055-410.1186/s12951-021-01055-4 ↗
26. 10.1016/j.freeradbiomed.2009.08.01810.1016/j.freeradbiomed.2009.08.018 ↗
27. 10.1002/adfm.20230782310.1002/adfm.202307823 ↗
28. 10.1002/anie.20190738810.1002/anie.201907388 ↗
29. 10.1016/j.cej.2022.13556710.1016/j.cej.2022.135567 ↗
30. 10.1021/acsami.9b1795110.1021/acsami.9b17951 ↗
31. 10.1002/adfm.20200857310.1002/adfm.202008573 ↗
32. 10.1021/acs.langmuir.6b0233110.1021/acs.langmuir.6b02331 ↗
33. 10.1021/jacs.7b1103610.1021/jacs.7b11036 ↗
34. 10.1002/advs.20230409210.1002/advs.202304092 ↗
35. 10.1016/j.cej.2023.14605410.1016/j.cej.2023.146054 ↗
36. 10.1186/s12951-022-01392-y10.1186/s12951-022-01392-y ↗
37. 10.1002/adhm.20230141310.1002/adhm.202301413 ↗
38. 10.1039/D0CC00763C10.1039/D0CC00763C ↗
39. 10.7150/thno.4507910.7150/thno.45079 ↗